Timing of anticoagulation for preventing blood clots in patients with brain hemorrhage
Early or Delayed Initiation of Venous Thromboembolism Prophylaxis With Heparin in Patients With Hypertensive Intracerebral Hemorrhage
This study is testing whether starting blood-thinning treatment early or later can help prevent blood clots in patients with bleeding in the brain while keeping them safe from more bleeding.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Pirogov Russian National Research Medical University Academic / other |
| Locations | 1 site (Moscow) |
| Trial ID | NCT06753786 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the safety and effectiveness of different timing for anticoagulation therapy using heparin to prevent venous thromboembolism in patients suffering from hypertensive intracerebral hemorrhage. Participants will be randomly assigned to receive anticoagulation either early, within the first two days after admission, or delayed, starting on the third day. The study aims to determine which timing minimizes the risk of bleeding complications while effectively preventing blood clots. The outcomes will help establish optimal guidelines for anticoagulation in this patient population.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with hypertensive intracerebral hemorrhage who meet the inclusion criteria.
Not a fit: Patients who have experienced intracerebral hemorrhage expansion, are on anticoagulants, or have other specified exclusion criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved protocols for preventing blood clots in patients with brain hemorrhages, potentially reducing complications and improving patient outcomes.
How similar studies have performed: While there have been studies on anticoagulation timing, this specific approach focusing on hypertensive intracerebral hemorrhage is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * the presence of hypertensive intracerebral hemorrhage Exclusion Criteria: * Intracerebral hemorrhage expansion detected on the basis of a computed tomography scan of the brain 12-24 hours after a hospital admission (i.e. before the initiation of venous thromboembolism prophylaxis with heparin) * Being on an anticoagulant during preadmission period and on day of hospital admission * Death within the first 2 days after hospital admission * Detection of venous thromboembolism in a patient at the moment of hospital admission * Surgical management of hypertensive intracerebral hemorrhage before the beginning of venous thromboembolism prophylaxis using heparin * The presence of a malignancy (cancer) in a patient at the moment of hospital admission
Where this trial is running
Moscow
- Moscow City Clinical Hospital named after V.M. Buyanov — Moscow, Russia (Recruiting)
Study contacts
- Study coordinator: Alexander Pryamikov, MD, PhD, Associate Professor
- Email: pryamikov80@rambler.ru
- Phone: +7 (903) 286-25-52
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.